Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Merck & Co (NY:MRK)

107.76 +0.36 (+0.34%)
Streaming Delayed Price Updated: 12:15 PM EST, Jan 27, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 3,530,131
Open 107.50
Bid (Size) 107.75 (100)
Ask (Size) 107.77 (100)
Prev. Close 107.40
Today's Range 106.84 - 108.35
52wk Range 73.31 - 112.90
Shares Outstanding 2,531,374,696
Dividend Yield 3.16%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
2 Pharmaceutical Stocks Set to Rebound in 2026 ↗
There might be massive upside ahead for these drugmakers. 
Via The Motley Fool
News headline image
Why Revolution Medicines Stock Plummeted by Almost 17% Today ↗
It doesn't look like the company will end up in the arms of an acquirer soon, after all. 
Via The Motley Fool

Performance

YTD
+1.2%
+1.2%
1 Month
+1.1%
+1.1%
3 Month
+22.5%
+22.5%
6 Month
+28.2%
+28.2%
1 Year
+10.0%
+10.0%

More News

Read More
News headline image
The Post-Keytruda Pivot: Inside Merck’s Strategic Evolution and the RVMD Landscape
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
Merck & Co. Inc. (NYSE:MRK) Stands Out as a High-Quality Dividend Stock ↗
Via Chartmill
MRNA Vs NVAX: Which Vaccine Stock Is Wall Street More Bullish On Right Now? ↗
Via Stocktwits
News headline image
The $6 Billion Disconnect: Why Revolution Medicines (RVMD) Plunged 20% After Merck Talks Collapsed
Via Finterra
Topics Economy Initial Public Offering
News headline image
Revolution Medicines Stock Sinks After Merck Deal Talks Collapse ↗
Via Benzinga
Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today ↗
Via Stocktwits
Topics Economy Stocks
News headline image
Revolution Medicines Stock Stares At Big Dip After Merck Reportedly Shelves Buyout — But Analyst Flags Opportunity ↗
Via Stocktwits
News headline image
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 ↗
Via The Motley Fool
Topics ETFs Intellectual Property World Trade
News headline image
2 Dirt Cheap Stocks to Buy With $200 Right Now ↗
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Should You Forget Eli Lilly and Buy These Unstoppable Stocks Instead? ↗
Via The Motley Fool
News headline image
2 Soaring Stocks to Hold for the Next 20 Years ↗
Via The Motley Fool
Topics Intellectual Property World Trade
News headline image
Stability Meets Scale: Why Johnson & Johnson is Poised for a Breakout 2026
Via MarketMinute
Topics Artificial Intelligence Bankruptcy Economy
News headline image
I Correctly Predicted That These 15 Dow Jones Stocks Would Boost Their Payouts in 2025. Here's Why It Can Happen Again in 2026. ↗
Via The Motley Fool
Topics Stocks
News headline image
Moderna and Merck Solidify Oncology Leadership as Five-Year Melanoma Data Fuels Market Rally
Via MarketMinute
Topics Intellectual Property
News headline image
Resilience in the Face of the Patent Cliff: Johnson & Johnson Forecasts Landmark 2026 Growth
Via MarketMinute
Topics Earnings Economy Intellectual Property
News headline image
Moderna’s 2026 Pivot: From Pandemic Pioneer to Oncology Powerhouse
Via Finterra
Topics Artificial Intelligence Economy Intellectual Property
News headline image
2 Healthcare Stocks with Solid Fundamentals and 1 That Underwhelm
Via StockStory
Topics Economy Stocks
News headline image
Why Moderna Stock Surged Today ↗
Via The Motley Fool
News headline image
Merck Shares Rise On $30M Funding From CEPI To Develop Affordable Ebola Vaccine ↗
Via Stocktwits
Topics Workforce
News headline image
Moderna Stock Still Worth 37% Less After Cancer Vaccine Data? BofA’s New Price Target Keeps Retail Traders Cautious ↗
Via Stocktwits
News headline image
Moderna Shares Rise On Five-Year Follow-Up Takeaways For Skin Cancer Vaccine: Retail Applauds ‘Solid’ Update ↗
Via Stocktwits
News headline image
GSK Challenges Xolair Dominance with $2.2 Billion Acquisition of RAPT Therapeutics
Via MarketMinute
Topics Intellectual Property
News headline image
Moderna & Merck Announce 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA(R) (pembrolizumab) Demonstrated Sustained Improvement in the Primary Endpoint of Recurrence-Free Survival in Patients With High-Risk Stage III/IV Melanoma Following
Via ACCESS Newswire

Frequently Asked Questions

Is Merck & Co publicly traded?
Yes, Merck & Co is publicly traded.
What exchange does Merck & Co trade on?
Merck & Co trades on the New York Stock Exchange
What is the ticker symbol for Merck & Co?
The ticker symbol for Merck & Co is MRK on the New York Stock Exchange
What is the current price of Merck & Co?
The current price of Merck & Co is 107.76
When was Merck & Co last traded?
The last trade of Merck & Co was at 01/27/26 12:15 PM ET
What is the market capitalization of Merck & Co?
The market capitalization of Merck & Co is 272.78B
How many shares of Merck & Co are outstanding?
Merck & Co has 273B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.